Pregnancy. Nursing mothers. See Contraindications. Concomitant moderate CYP3A inducers: not recommended. May be potentiated by combined P-gp, UGT1A1, and strong CYP3A inhibitors: concomitant use ...

The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in ...

Concomitant strong or moderate CYP3A inducers: Avoid use with Nurtec ODT; may lead to loss of efficacy. Concomitant potent inhibitors of P-gp: Avoid another dose of Nurtec ODT within 48 hours.